Strong Trial Results, Effective Distribution Could Put Regeneron's Praluent 'Back In The Competition'
March 12, 2018 at 13:39 PM EDT
Regeneron Pharmaceuticals Inc (NASDAQ: REGN)’s promising Praluent trial outcomes — and an effective marketing strategy to ...